FDA Clears J&J’s IMAAVY as First Drug for Rare Blood Disease
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) secured U.S. Food and Drug Administration approval for IMAAVY to treat warm autoimmune hemolytic anemia in patients 12 and older who …
FDA Clears J&J’s IMAAVY as First Drug for Rare Blood Disease Read More